Page last updated: 2024-11-08

2'-amino-2'-deoxyadenosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID447594
CHEMBL ID133809
SCHEMBL ID598130
MeSH IDM0045122

Synonyms (25)

Synonym
(2r,3s,4r,5r)-4-amino-5-(6-aminopurin-9-yl)-2-(hydroxymethyl)tetrahydrofuran-3-ol
4-amino-5-(6-amino-purin-9-yl)-2-hydroxymethyl-tetrahydro-furan-3-ol
10414-81-0
DB04102
2AD ,
CHEMBL133809 ,
2''-amino-2''-deoxyadenosine ,
bdbm50106536
cid_100053
2'-amino-2'-deoxyadenosine
adenosine, 2'-amino,-2'-deoxy-
2'-deoxy-2'-aminoadenosine
9-(2-amino-2-deoxyfuranosyl)adenine
nsc 324326
AKOS016003830
HG1019
SCHEMBL598130
CQKMBZHLOYVGHW-QYYRPYCUSA-N
adenosine, 2'-amino-2'-deoxy-
mfcd06657636
AS-49373
2-amino-2-deoxyadenosine
Q27452838
CS-W012428
PD059384
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine receptor A3Homo sapiens (human)Ki500.15050.00000.930610.0000AID34581; AID34704
Adenosine receptor A1Rattus norvegicus (Norway rat)Ki0.01000.00011.20929.9700AID31884
Adenosine receptor A3Rattus norvegicus (Norway rat)Ki0.01000.00030.91969.0000AID33335
Adenosine receptor A2aRattus norvegicus (Norway rat)Ki0.01000.00021.494010.0000AID32861
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (11)

Processvia Protein(s)Taxonomy
inflammatory responseAdenosine receptor A3Homo sapiens (human)
signal transductionAdenosine receptor A3Homo sapiens (human)
activation of adenylate cyclase activityAdenosine receptor A3Homo sapiens (human)
regulation of heart contractionAdenosine receptor A3Homo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A3Homo sapiens (human)
response to woundingAdenosine receptor A3Homo sapiens (human)
regulation of norepinephrine secretionAdenosine receptor A3Homo sapiens (human)
negative regulation of cell migrationAdenosine receptor A3Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityAdenosine receptor A3Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A3Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (1)

Processvia Protein(s)Taxonomy
G protein-coupled adenosine receptor activityAdenosine receptor A3Homo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2aRattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
plasma membraneAdenosine receptor A3Homo sapiens (human)
presynaptic membraneAdenosine receptor A3Homo sapiens (human)
Schaffer collateral - CA1 synapseAdenosine receptor A3Homo sapiens (human)
dendriteAdenosine receptor A3Homo sapiens (human)
plasma membraneAdenosine receptor A3Homo sapiens (human)
synapseAdenosine receptor A3Homo sapiens (human)
Golgi membraneAdenosine receptor A2aRattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID32861Binding affinity at rat brain Adenosine A2A receptor in CHO cells2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
Neoceptor concept based on molecular complementarity in GPCRs: a mutant adenosine A(3) receptor with selectively enhanced affinity for amine-modified nucleosides.
AID34581Binding affinity at Mutant (H272E) human adenosine A3 receptor expressed in COS-7 cells2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
Neoceptor concept based on molecular complementarity in GPCRs: a mutant adenosine A(3) receptor with selectively enhanced affinity for amine-modified nucleosides.
AID31884Binding affinity at rat brain Adenosine A1 receptor2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
Neoceptor concept based on molecular complementarity in GPCRs: a mutant adenosine A(3) receptor with selectively enhanced affinity for amine-modified nucleosides.
AID34704Binding affinity at wild-type Adenosine A3 receptor expressed in COS-7 cells2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
Neoceptor concept based on molecular complementarity in GPCRs: a mutant adenosine A(3) receptor with selectively enhanced affinity for amine-modified nucleosides.
AID33335Binding affinity at rat adenosine A3 receptor in RBL-2H3 cells2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
Neoceptor concept based on molecular complementarity in GPCRs: a mutant adenosine A(3) receptor with selectively enhanced affinity for amine-modified nucleosides.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (60.00)18.7374
1990's0 (0.00)18.2507
2000's4 (40.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.74 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.14 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.74)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]